Novavax Inc (NVAX.OQ)

NVAX.OQ on NASDAQ Stock Exchange Global Select Market

27 Feb 2015
Change (% chg)

$-0.16 (-1.72%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for NVAX.OQ


Novavax, Inc. (Novavax) is a clinical stage biopharmaceutical company. The Company focuses on developing recombinant vaccines. The Company’s technology platform is based on recombinant vaccine technology that includes the virus-like particles (VLPs). The Company's vaccine candidates are genetically engineered three-dimensional... (more)


Beta: 1.26
Market Cap(Mil.): $2,225.00
Shares Outstanding(Mil.): 238.48
Dividend: --
Yield (%): --


  NVAX.OQ Industry Sector
P/E (TTM): -- 175.70 40.21
EPS (TTM): -0.30 -- --
ROI: -25.94 -2.61 16.34
ROE: -27.37 -4.38 17.27
Search Stocks

Novavax starts Ebola vaccine trial in humans

- Novavax Inc has begun early-stage human trials of an Ebola vaccine that it hopes can win the race to become the most effective shot for the deadly virus.

12 Feb 2015

UPDATE 1-Novavax starts Ebola vaccine trial in humans

* Co says can manufacture millions of doses a month (Adds CEO comment, detail)

12 Feb 2015

Novavax starts Ebola vaccine trial in humans

Feb 12 - Novavax Inc has begun early-stage testing of its Ebola vaccine in humans, the company said, less than five months after entering the race to develop a shot for the deadly virus.

12 Feb 2015


  Price Chg
Novartis AG (NOVN.VX) CHF97.45 --
Merck & Co., Inc. (MRK.N) $58.54 -0.42
Sanofi SA (SASY.PA) €87.70 --
GlaxoSmithKline plc (GSK.L) 1,541.50p --
AstraZeneca plc (AZN.L) 4,469.50p --

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
Provider: S&P Capital IQ Quantitative Report
Provider: Reuters Investment Profile
Provider: Thomson Reuters Stock Report
Provider: New Constructs, LLC

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks